Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Checkpoint Trends Ltd

₹ 1241.97%
14 Jan – close price
🔗rubramed.comâ€ĸBSE: 531099â€ĸNSE:
Market Cap₹ 67.9 Cr.
Current Price₹ 124
High / Low₹ 144
Stock P/E46.8
Book Value₹ 3.60
Dividend Yield0.00 %
ROCE16.5 %
ROE9.17 %
Face Value₹ 10.0
Sales₹ 121 Cr.
OPM1.61 %
Mar Cap₹ 67.9 Cr.

ABOUT

Incorporated in 1991, Checkpoint Trends Ltd is in the business of trading and consultancy[1]

KEY POINTS

Business Overview:[1]CTL (Formerly Rubra Medicaments Ltd) was engaged in the manufacture and sale of pharmaceutical formulations based in Hyderabad. The company is currently in the business of trading and providing different kinds of consulting services in India to all categories of clients.

Also present in buckets:
Aggressive Growth TriggersExcellent ResultsRevenue GuidanceAsset Base ExpansionCapacity Expansion And ProductsPreferential IssuanceJv Partnerships AcquisitionsRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1700.7035.35408054.900.943124.952.5614478.318.9320.2154964.0130.1211543.963117.955.2412.970.07
2.Divi's Lab.6355.5067.89168718.560.47689.0035.102715.0016.1220.4410029.0032.372485.00689.0010.9513.530.01
3.Torrent Pharma.4003.7062.54135503.400.80591.0032.493302.0014.3027.0512248.0032.602166.53600.1716.0413.260.33
4.Cipla1434.5021.30115874.780.911353.373.737589.447.6422.7228349.5725.405441.141351.173.5214.720.01
5.Lupin2195.9023.19100308.450.551484.8373.347047.5124.2321.3024750.6927.254324.631477.925.1112.410.32
6.Dr Reddy's Labs1186.5017.1699028.890.671336.807.288828.309.8322.6934310.0024.645772.201347.102.7512.950.16
7.Mankind Pharma2244.4052.9992649.970.04520.18-22.003697.1620.7715.9813545.6724.121748.55511.516.068.890.55
8.Checkpoint Trend124.1546.8367.910.001.323400.00108.59217080.0016.51120.651.611.451.3234.466.330.00
–Median: 149 Co.394.529.561738.640.1213.4911.71161.7610.5814.89591.7315.9345.2613.963.148.560.22

Quarterly Results

Standalone figures in ₹ crores

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales
0.360.210.080.200.290.170.470.100.050.100.2511.71108.59
Expenses
0.350.210.190.250.030.110.710.070.080.140.1611.62106.79
Operating Profit
0.010.00-0.11-0.050.260.06-0.240.03-0.03-0.040.090.091.80
Other Income
0.000.000.000.000.000.000.000.000.000.02-0.020.000.00
Profit before tax
0.010.00-0.11-0.050.260.06-0.240.03-0.03-0.020.070.091.80
Tax %
0.00%–-9.09%0.00%0.00%0.00%-4.17%0.00%33.33%0.00%0.00%0.00%26.11%
Net Profit
0.010.00-0.10-0.050.260.06-0.230.02-0.04-0.020.060.091.32
EPS in Rs
0.020.00-0.18-0.090.480.11-0.420.04-0.07-0.040.110.162.41

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
-0-00021102110121
Expenses
000021102110119
Operating Profit
-0-0-00-0-000-0-0002
Other Income
-0-3-0-0-000-0-0-0-0-00
Interest
-0-0-0-0-0-0-0-0-0-0-0-00
Depreciation
-0-0-0-0-0-0-0-0-0-0000
Profit before tax
-0-3-00-0-000-0-0002
Net Profit
-0-3-00-0-000-0-0001
EPS in Rs
-0.11-5.61-0.020.05-0.29-0.020.050.02-0.07-0.150.050.052.64
Dividend Payout %
-0%-0%-0%-0%-0%-0%-0%-0%-0%-0%-0%-0%–

Compounded Sales Growth

10 Years:%
5 Years:-13%
3 Years:-37%
TTM:15172%

Compounded Profit Growth

10 Years:11%
5 Years:38%
3 Years:48%
TTM:863%

Stock Price CAGR

10 Years:%
5 Years:123%
3 Years:202%
1 Year:1032%

Return on Equity

10 Years:-1%
5 Years:-1%
3 Years:0%
Last Year:9%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
5555555555555
Reserves
-2-5-5-5-5-5-5-5-5-5-5-5-4
Borrowings
0-0-0-0-0-0-0-0-00-0-0-0
Other Liabilities
000000000-000139
Total Liabilities
400111111111141
Fixed Assets
-0-0-0-0-0000000-00
Gross Block
0.000.000.000.000.000.020.020.020.020.060.070.00–
Accumulated Depreciation
–––––––––––––
CWIP
-0-0-0-0-0-0-0-0-0-0-0-0-0
Investments
-0-0-0-0-0-0-0-0-0-0-0-0-0
Other Assets
400111111111141
Total Assets
400111111111141

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
-0-0-000-001-00-00
Cash from Investing Activity
-0-0-0-0-0-0-0-0-0-0-0-0
Cash from Financing Activity
0-0-00-0-0-0-0-0-0-0-0
Net Cash Flow
0-0-000-0-01-00-00

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
––362454179107164122135229212
Inventory Days
––-0-0-0-0-0-0-0–––
Days Payable
––––––––––––
Cash Conversion Cycle
––362454179107164122135229212
Working Capital Days
––18-35362602216098129145387
ROCE %
-2%-3%-3%7%25%-31%3%2%-3%-13%3%17%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters
–––––––––––––
FIIs
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%10.85%10.86%10.86%10.71%
DIIs
–––––––––––––
Public
100.00%100.00%100.00%100.00%100.00%100.00%100.00%99.99%100.00%89.14%89.15%89.14%89.29%

* The classifications might have changed from Sep'2022 onwards.ℹī¸

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Centuple Global Limited files SEBI Regulation 74(5) Confirmation for March 31, 2026 Quarter

9th April 2026, 7:41 pm

Centuple Global Limited to Close Trading Window from April 1 for Financial Results

24th March 2026, 7:58 pm

Centuple Global Limited Board Accepts Director Resignations, Appoints New Independent Directors

18th March 2026, 10:35 pm

Centuple Global Approves Allotment of 1.66 Crore Warrants Worth ₹75.05 Crore

6th March 2026, 2:49 am

Centuple Global Approves Allotment of 1.66 Cr Warrants Worth ₹75.05 Crore

6th March 2026, 2:47 am

Published by Other Websites

External media mentions & references

iValue Infosolutions Gets 'Buy' Call, Broker Sets ₹330 Target

16th April 2026, 5:52 pm

Documents

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

1d - Compliance certificate for the quarter ended December 31, 2025

Closure of Trading Window

29 Dec - Trading window closed from Jan 1, 2026 until 48 hours after unaudited Q3 (Dec 31, 2025) results.

Non-Applicability Of Secretarial Compliance Report For The Year Ended March 31, 2025

26 Dec - Checkpoint Trends: Reg 24A not applicable; paid-up capital ≤₹10cr and net worth ≤₹25cr as of Mar 31, 2025.

Compliances-Reg.24(A)-Annual Secretarial Compliance

26 Dec - Regulation 24A not applicable; paid-up equity ≤ Rs10 crore, net worth ≤ Rs25 crore for FY ended March 31, 2025.

Non-Applicability Of Secretarial Compliance Report For The Year Ended March 31, 2022

26 Dec - Reg 24A not applicable; paid-up equity ≤ Rs10 crore, net worth ≤ Rs25 crore for FY ended Mar 31, 2022.

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from bse)

Financial Year 2012

(from bse)

Financial Year 2011

(from bse)

Credit Ratings

No credit ratings.

Concalls

No concalls.

Stock Analysis

Description

  1. Incorporated in 1991, Checkpoint Trends Ltd is in the business of trading and consultancy. The company was previously involved in pharmaceutical formulations.

Key Growth Triggers

  1. Strategic diversification into tobacco and FMCG sectors.
  2. Planned capital raising through preferential warrants and QIP to fund expansion and working capital.
  3. Incorporation of a wholly-owned subsidiary in the United Kingdom for international expansion.
  4. Acquisition of Global Tobacc Legacy to strengthen its position in the tobacco segment.

Order Book

Currently no data available for Order Book.

Key Red Flags

  1. Stock trading at a high price-to-book value (33.8x).
  2. Poor historical sales growth (-12.8% over five years).
  3. High debtors days (212 days) and increased working capital days (387 days).

Corporate Announcements

9th Apr 26
Impact Rating: 3
The company confirms dematerialized securities were processed, original certificates cancelled, and member register updated, in line with SEBI regulations for the period.
24th Mar 26
Impact Rating: 7
Centuple Global Limited's trading window for equity shares will be closed from April 1, 2026, in anticipation of its audited financial results for the quarter and year ending March 31, 2026.
18th Mar 26
Impact Rating: 6
Centuple Global Limited announced the resignation of Ms. Bhawna Saunkhiya and Mr. Saurabh as Independent Directors and appointed Mr. Ashish Jain and Mr. Gaurav Kaushik for a 5-year term, pending member approval.
5th Mar 26
Impact Rating: 7
Centuple Global's board approved allotting 1.66 crore warrants at ₹45.01 each, worth ₹75.05 crore. Investors paid 25% upfront, totaling ₹18.76 crore. Warrants are exercisable within 18 months.
5th Mar 26
Impact Rating: 8
Centuple Global Limited's Board has approved the allotment of 1,66,74,072 convertible warrants at ₹45.01 per warrant, totalling ₹75.05 crore. The company received ₹18.76 crore (25% of the issue price) upfront from nine investors.